$2.3M NIH Grant Catalyzes $26.5M Series B to Advance Probiotic Treatments for Necrotizing Enterocolitis and Autism
$2.3M
Non-dilutive funding awarded
Scioto Biosciences was founded to advance a promising treatment for necrotizing enterocolitis (NEC), a life-threatening condition in premature infants. In partnership with EGC, the company developed and executed a targeted grant strategy, successfully securing over $2.3M in NIH funding to support clinical development.
With this critical early stage funding, Scioto progressed its microbiome platform through key milestones, generating positive Phase II results and expanding into additional indications, including autism spectrum disorder.
The company’s promising results led to a $26.5M Series B investment, positioning the company to advance its technology across multiple high-impact diseases.
“The team is always easy to work with, knowledgeable of the areas and very well organized to get the projects completed on time.”
– Jim Schulz, CFO, Scioto Biosciences
Funding Sources
